Navigation Links
Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
Date:4/7/2008

TORONTO, April 7 /PRNewswire/ - Medical Futures Inc. has licensed MUTAFLOR(R) for the North American market. MUTAFLOR(R) is a drug used in remission maintenance of Ulcerative Colitis. Since its discovery in 1917, MUTAFLOR(R) has been available in the German marketplace through a subsidiary of Pharma-Zentrale GmbH, Ardeypharm GmbH. MUTAFLOR(R) has shown clinical efficacy in phase III clinical trials and has shown a perfect safety record since 1917. Ulcerative colitis is an Inflammatory Bowel Disease that affects 500,000 Americans and 60,000 Canadians.

"Medical Futures Inc. is excited about partnering with Pharma-Zentrale GmbH for MUTAFLOR(R)," says Dr. Par Nijhawan, Chief Medical Officer of Medical Futures Inc., who believes that MUTAFLOR(R) will help improve the options available for Ulcerative Colitis patients.

"Medical Futures has created a therapeutic focus and a strong product offering for the gastroenterology market in North America," says Hans Proppert, President and Chief Executive Officer of Pharma Zentrale GmbH. "With MUTAFLOR(R) in their capable hands, we are confident of its success in an important market for us."

About MUTAFLOR(R)

MUTAFLOR(R) has data proving equal efficacy when compared to 5-ASA products in remission maintenance of Ulcerative Colitis. It is taken as an oral capsule format that saves patients from intravenous infusions or self administration of subcutaneous needles. This, together with the clinical evidence, is one advantage of MUTAFLOR(R) over all other biologics available on the market.

About Medical Futures Inc.

Medical Futures Inc. is a niche pharmaceutical company that has a focus on gastrointestinal therapy. Medical Futures is dedicated to improving quality of life and provides safe, effective and affordable medicines. These medicines include:

Florastor(TM): The world's number one probiotic that has proven efficacy in treating and preventing diarrhea from various causes including Pediatric Diarrhea, Antibiotic Associated, Clostridium Difficile and Travellers' Diarrhea.

Iberogast(R): The only treatment available for Non-ulcer Dyspepsia and Irritable Bowel Syndrome.

Zingo(TM) is a needle-free, easy-to-administer, single-use system that delivers sterile lidocaine powder into the epidermis of the skin that provides topical, local analgesia in one minute.

SANVAR(R) is the only somatostatin analogue to have demonstrated statistically significant benefits in the treatment of esophageal variceal bleeding in association with endoscopic therapy in a placebo-controlled clinical study (NEJM, 2001).


'/>"/>
SOURCE Medical Futures Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
Breaking Medicine Technology: